New long-term data from the Phase III FLAURA2 trial confirm that Tagrisso combined with chemotherapy delivers a significant overall survival benefit over monotherapy in patients with advanced ...

Tagrisso with chemo significantly improved survival and progression-free outcomes versus Tagrisso alone in newly diagnosed ...

Subjects in the trial received 80mg of Tagrisso daily in oral tablet form, combined with a chemotherapy regimen.

AstraZeneca announces positive results from FLAURA2 phase III trial of Tagrisso plus chemotherapy to treat EGFR-mutated advanced lung cancer: Cambridge, UK Tuesday, July 22, 2025, ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 ...

The trial's principal investigator Pasi Janne said the results support osimertinib "as standard of care" for EGFR-mutated cancer patients. Janne also noted that AstraZeneca's drug "did not impose any ...

Positive high-level results have been presented from the final overall survival (OS) analysis of the FLAURA2 Phase III trial.

AstraZeneca has bolstered the standing of Tagrisso as a first-line treatment for locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) with new long-term overall survival (OS) ...

AstraZeneca (AZ) has shared positive overall survival (OS) results from a late-stage study of its epidermal growth factor ...

The selection of a first-line treatment for patients with advanced EGFR -positive non-small cell lung cancer (NSCLC) has ...

ORPATHYS ® is approved in China and is marketed by AstraZeneca for the treatment of adult patients with locally advanced or metastatic NSCLC with MET exon 14 skipping alteration, representing the ...